CORDIS
EU research results

CORDIS

English EN

The CLIO consortium: Optimization of Cerenkov Luminescence Imaging for Image-Guided Cancer Surgery

Project information

Grant agreement ID: 606614

Status

Closed project

  • Start date

    1 January 2014

  • End date

    30 November 2016

Funded under:

FP7-SME

  • Overall budget:

    € 1 721 137,79

  • EU contribution

    € 1 332 999,99

Coordinated by:

CROMED KUTATO ES SZOLGALTATO KOZPONTOK KFT

Hungary

Objective

Cancer is the second largest cause of death and morbidity in Europe, with more than 3 million new cases diagnosed each year. The most effective treatment strategy for most forms of cancer is early detection followed by surgery. However, cancers frequently recur following surgery. For example, nearly 1 in 4 breast cancer patients will see their tumour recur after surgery. The consequences of cancer recurrence include repeat operations, delayed adjuvant treatment, increased likelihood of distant recurrence, poorer cosmetic and functional outcomes, emotional distress, and financial cost. The financial costs are staggering. Europe spends €125 billion annually on cancer care, approximately 5% of which is managing post-surgical recurrence.

Tumours recur after surgery primarily due to incomplete excision of the tumour or inadequate clearance of surgical margins. Tumours fail to be completely excised because the surgeon only has the visual appearance of the tumor and palpation to differentiate malignant from benign tissue. Consequently, there is an urgent clinical and market need for improved tools to detect cancerous tissue during surgery.

Real-time imaging during surgery would enable the surgeon to more accurately resect tumors and thereby reduce the likelihood of post-surgical recurrence. Cerenkov luminescence imaging (CLI) is a ground-breaking imaging modality that can provide real-time molecular imaging during surgery

The CLIO consortium will develop a Cerenkov luminescence imaging device and a handheld intraoperative beta particle imaging device for image-guided surgery as well as imaging services for the pharmaceutical and medical device sectors. The imaging services will enable pharmaceutical and medical device clients to improve the efficacy evaluation of pharmaceutical and surgical device products. The consortium contains world-leading expertise in medical device product development, clinical and preclinical imaging, oncologic surgery, and surgical device evaluation.

Coordinator

CROMED KUTATO ES SZOLGALTATO KOZPONTOK KFT

Address

Baross Utca 91 95
1047 Budapest

Hungary

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 614 521,90

Administrative Contact

Mariann Semjeni (Ms.)

Participants (6)

ORSZAGOS FREDERIC JOLIOT-CURIE SUGARBIOLOGIAI ES SUGAREGESZSEGUGYI KUTATO INTEZET

Hungary

ABX CRO ADVANCED PHARMACEUTICAL SERVICES FORSCHUNGSGESELLSCHAFT MBH

Germany

EU Contribution

€ 108 583,97

LIGHTPOINT MEDICAL LTD

United Kingdom

EU Contribution

€ 609 894,12

SAGENTIA LIMITED

United Kingdom

SEMMELWEIS EGYETEM

Hungary

NEMZETI NEPEGESZSEGUGYI KOZPONT

Hungary

Project information

Grant agreement ID: 606614

Status

Closed project

  • Start date

    1 January 2014

  • End date

    30 November 2016

Funded under:

FP7-SME

  • Overall budget:

    € 1 721 137,79

  • EU contribution

    € 1 332 999,99

Coordinated by:

CROMED KUTATO ES SZOLGALTATO KOZPONTOK KFT

Hungary